Table 1. Baseline characteristics for participants.
| Women (N = 1,527) | Men (N = 1,166) | |
|---|---|---|
| Age | 72.38 ±6.81 | 72.04 ±6,51 |
| Metabolic Syndrome (n, %) | 698 (45.7) | 435 (37,3) |
| Bone mineral density, 1st round (g/cm2) | 0.82 ± 0.14 | 0.93 ± 0.14 |
| Bone mineral density, 2nd round (g/cm2)* | 0.82 ± 0.13 | 0.92 ± 0.13 |
| Cortical thickness (cm)** | 0.13 ± 0.04 | 0.15 ± 0.03 |
| Bone width (cm)** | 2.93 ± 0.32 | 3.37 ± 0.30 |
| Section modulus (cm3)** | 0.97 ± 0.31 | 1.41 ± 0.34 |
| Cortical buckling ratio** | 13.50 ± 5.00 | 13.15 ± 3.96 |
| Osteoporosis (n, %) | 278 (18.2) | 172 (14.8) |
| Osteopenia (n, %) | 855 (56.0) | 640 (54.6) |
| Diabetes Mellitus (n,%) | 194 (12.7) | 172 (14.8) |
| BMI (kg/m2) | 27.15 ±4.25 | 26.35 ±3.19 |
| Smoking (Yes) (n,%) | 216 (14.0) | 201 (17.2) |
| Physical activity (min/week) | 2820.62 ±1103.74 | 2519.15 ±1178 |
| Alcohol intake (g/day) | 1,57 (396821.4) | 4.29 (79364.3) |
| Dutch Healthy Diet-Index | 50.84 ±9.92 | 45.55 ±9.78 |
| Fallings in the last 12 months (n, %) | 415 (27.2) | 225 (19.3) |
| Diuretic drugs (n,%) | 264 (17.3) | 163 (14.0) |
| HRT (n,%) | 66 (4.3) | 3 (0.26) |
| Corticosteroid drugs (n,%) | 51 (3.3) | 25 (2.1) |
| Bone drugs (n,%) | 56 (3.86) | 6 (0.53) |
| Other musculoskeletal drugs (n,%) | 32 (2.1) | 6 (0.53) |
HRT: Hormone replacement therapy
*999 female and 768 male individuals with available measure of BMD at the second round
**1,403 female and 1,118 male individuals with available measure of hip bone geometry